48,994 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by McGowan Group Asset Management Inc.

McGowan Group Asset Management Inc. purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 48,994 shares of the specialty pharmaceutical company's stock, valued at approximately $6,034,000. McGowan Group Asset Management Inc. owned about 0.08% of Jazz Pharmaceuticals as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of JAZZ. Fuller & Thaler Asset Management Inc. increased its holdings in Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock valued at $115,681,000 after buying an additional 507,234 shares during the last quarter. Darwin Global Management Ltd. purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $59,668,000. Dimensional Fund Advisors LP lifted its position in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after buying an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after purchasing an additional 315,608 shares during the last quarter. Finally, GMT Capital Corp boosted its holdings in shares of Jazz Pharmaceuticals by 140.0% during the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock worth $62,659,000 after buying an additional 296,800 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total transaction of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at approximately $66,940,366.50. This represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,236 shares of company stock worth $3,956,190. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $103.58 on Tuesday. The stock has a 50-day simple moving average of $118.23 and a 200 day simple moving average of $122.25. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $6.38 billion, a price-to-earnings ratio of 14.59, a P/E/G ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company's revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.68 EPS. On average, research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Barclays reiterated an "overweight" rating and issued a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. HC Wainwright increased their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.